bupropion has been researched along with paroxetine in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (7.69) | 18.2507 |
| 2000's | 34 (43.59) | 29.6817 |
| 2010's | 35 (44.87) | 24.3611 |
| 2020's | 3 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Preskorn, SH | 1 |
| Liebowitz, MR; Marshall, RD | 1 |
| DePalma, RL; Katholi, CR; Modell, JD; Modell, JG | 1 |
| Grimes, JB; Hines, A; Labbate, LA; Pollack, MH | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Roose, SP; Spatz, E | 1 |
| Ascher, JA; Batey, SR; Donahue, RM; Houser, TL; Settle, EC; Weihs, KL | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Dewan, V | 1 |
| Klein, RM; Walker, JB; Yee, SL | 1 |
| Bagby, RM; Kennedy, SH; Vanderkooy, JD | 1 |
| Baker, GB; Kennedy, SH; Masellis, M; McCann, SM; McIntyre, RS; McKay, G; Raskin, J | 1 |
| Asnis, GM; Gabbay, V; O'Dowd, MA | 1 |
| Begley, AE; Joo, JH; Lenze, EJ; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Weber, EM | 1 |
| Bourin, M; Dailly, E; David, DJ; Hascoët, M; Ripoll, N | 1 |
| DeVane, CL | 1 |
| Nemeroff, CB | 1 |
| Allen, MT; Girdler, SS; Golding, M; Light, KC; Straneva-Meuse, PA | 1 |
| Altschuler, EL; Kast, RE | 1 |
| Malik, AR; Ravasia, S; Wolf, PK | 1 |
| Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Chung, JY; Frank, L; Green, BL; Krupnick, J; Miranda, J; Prasad, M; Revicki, DA; Siddique, J | 1 |
| Belin, T; Chung, J; Green, BL; Krupnick, JL; Miranda, J; Revicki, D; Siddique, J | 1 |
| Bagby, RM; Cohen, NL; Fulton, KA; Greene, AL; Kennedy, SH; Rafi-Tari, S | 1 |
| Edwards, JL | 1 |
| Braun, M; Connemann, BJ; Freudenmann, RW; Schönfeldt-Lecuona, C; Wolf, RC | 1 |
| Bensasi, S; Houck, PR; Lenze, EJ; Miller, MD; Mulsant, BH; Reynolds, CF; Stack, JA; Tew, JD; Whyte, EM | 1 |
| Allen, MH; Bowden, CL; Calabrese, JR; Dennehy, EB; Fossey, MD; Friedman, ES; Gyulai, L; Hauser, P; Ketter, TA; Marangell, LB; Martinez, JM; Miklowitz, DJ; Nierenberg, AA; Ostacher, MJ; Otto, MW; Patel, J; Rapport, D; Sachs, GS; Thase, ME; Wisniewski, SR | 1 |
| Dobkin, RD; Marin, H; Menza, MA | 1 |
| Bensasi, S; Dew, MA; Houck, PR; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Whyte, EM | 1 |
| Silva, RR | 1 |
| Gomeni, R; Merlo-Pich, E | 1 |
| Guardia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, J; Herrera-Guzmán, D; Herrera-Guzmán, I; Lira-Mandujano, J; Montoya-Pérez, K | 1 |
| Billups, SJ; Delate, T; Dugan, D | 1 |
| Bekkering, GE; Tuinier, S; Verbeeck, W | 1 |
| Howland, RH | 1 |
| LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
| Abler, B; Grön, G; Hartmann, A; Metzger, C; Seeringer, A; Stingl, J; Walter, M | 1 |
| Burke, AK; Duan, N; Ellis, SP; Grunebaum, MF; John Mann, J; Oquendo, MA | 1 |
| Abler, B; Seeringer, A; Stingl, JC; Viviani, R | 1 |
| Dhamee, MS; Gollapudy, S; Kumar, V | 1 |
| Humpston, CS; Robinson, ES; Wood, CM | 1 |
| Abler, B; Graf, H; Hartmann, A; Metzger, CD; Walter, M | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Bauer, N; Burke, AK; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA; Sudol, K | 1 |
| Bijlsma, EY; Chan, JS; Millan, MJ; Olivier, B; Oosting, RS; Veening, JG; Waldinger, MD | 1 |
| Abler, B; Graf, H; Metzger, CD; Walter, M | 2 |
| Blier, P; Chenu, F; El Iskandrani, KS; El Mansari, M; Manta, S; Oosterhof, C; Shim, S | 1 |
| Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N | 1 |
| Mimura, M; Mizushima, J; Nio, S; Suzuki, T; Tada, M; Uchida, H | 1 |
| Buoli, M; Cahn, W; Serati, M | 1 |
| Dudka, J; Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E | 1 |
| Burke, AK; Ellis, SP; Gorlyn, M; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA | 1 |
| Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Carvalho, AF; Chaves Filho, AJM; de Sousa, FCF; Hyphantis, TN; Macêdo, D; McIntyre, RS; Menezes, CES; Quevedo, J; Vasconcelos, SMM | 1 |
| Bulmus, O; Canpolat, S; Colakoglu, N; Kaya, N; Kelestimur, H; Ozcan, M; Ulker, N; Yardimci, A | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| Canpolat, S; Colakoglu, N; Kaya Tektemur, N; Kelestimur, H; Ozcan, M; Ulker, N; Yardimci, A | 1 |
| Camino, S; Godoy, A; Smith, J; Strejilevich, SA; Szmulewicz, A | 1 |
| Gedde-Dahl, A; Molden, E; Spigset, O | 1 |
12 review(s) available for bupropion and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Treatment of depression in patients with heart disease.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Comorbidity; Death, Sudden; Depressive Disorder; Double-Blind Method; Heart Block; Heart Diseases; Humans; Hypotension, Orthostatic; Myocardial Ischemia; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Ventricular Fibrillation | 1999 |
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Drug Tolerance; Half-Life; Humans; Nausea; Paroxetine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2003 |
Improving antidepressant adherence.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Health Promotion; Humans; Paroxetine; Patient Compliance; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2003 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Bupropion; Comorbidity; Desipramine; Evidence-Based Medicine; Humans; Lithium Carbonate; Monoamine Oxidase Inhibitors; Paroxetine; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Buspirone; Cyclohexanols; Disease Models, Animal; Dopamine; Female; Humans; Indoles; Male; Norepinephrine; Paroxetine; Pyridines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Synaptic Transmission; Venlafaxine Hydrochloride | 2014 |
Antidepressant-related sexual dysfunction - perspectives from neuroimaging.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Female; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Psychopharmacology; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological | 2014 |
Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
Topics: Adrenergic alpha-Agonists; Adult; Amphetamines; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Central Nervous System Stimulants; Desipramine; Dopamine Agents; Droxidopa; Drug Combinations; Duloxetine Hydrochloride; Guanfacine; Histamine Agents; Humans; Lisdexamfetamine Dimesylate; Lithium Compounds; Lobeline; Mecamylamine; Memantine; Modafinil; Morpholines; Nicotinic Agonists; Nicotinic Antagonists; Nomifensine; Paroxetine; Pyridines; Pyridoxine; Pyrrolidonecarboxylic Acid; Quinazolinones; Reboxetine; Venlafaxine Hydrochloride; Wakefulness-Promoting Agents | 2016 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Are all antidepressants the same? The consumer has a point.
Topics: Antidepressive Agents; Bupropion; Citalopram; Fluoxetine; Humans; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2023 |
20 trial(s) available for bupropion and paroxetine
| Article | Year |
|---|---|
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risk Factors; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2000 |
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Dopamine Uptake Inhibitors; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Bupropion; Cross-Sectional Studies; Dose-Response Relationship, Drug; Epinephrine; Heart Rate; Humans; Hydrocortisone; Neurosecretory Systems; Paroxetine; Stress, Psychological | 2004 |
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Community Mental Health Services; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Female; Health Care Costs; Health Status; Humans; Minority Groups; Paroxetine; Poverty; Quality of Life; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome | 2005 |
One-year outcomes of a randomized clinical trial treating depression in low-income minority women.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Minority Groups; Paroxetine; Patient Education as Topic; Poverty; Psychotherapy, Group | 2006 |
Sexual function during bupropion or paroxetine treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Distribution; Sexual Dysfunction, Physiological | 2006 |
Impact of prior treatment exposure on response to antidepressant treatment in late life.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lithium Carbonate; Long-Term Care; Male; Nortriptyline; Paroxetine; Psychotherapy; Retreatment; Treatment Failure; Treatment Outcome | 2006 |
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Bupropion; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Treatment Outcome | 2007 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Bupropion; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion.
Topics: Adult; Antidepressive Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Humans; Limbic System; Magnetic Resonance Imaging; Male; Neurons; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Young Adult | 2011 |
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide; Treatment Outcome | 2012 |
Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Bupropion; Cerebrovascular Circulation; Double-Blind Method; Humans; Male; Paroxetine; Spin Labels; Young Adult | 2012 |
Modulation of attention network activation under antidepressant agents in healthy subjects.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Attention; Brain; Brain Mapping; Bupropion; Cross-Over Studies; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Oxygen; Paroxetine; Photic Stimulation; Reaction Time; Surveys and Questionnaires; Young Adult | 2013 |
SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide, Attempted; Young Adult | 2013 |
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Suicidal Ideation; Suicide, Attempted; Treatment Outcome | 2015 |
Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data.
Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome | 2015 |
Serotonergic antidepressants decrease hedonic signals but leave learning signals in the nucleus accumbens unaffected.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Cross-Over Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Erotica; Functional Laterality; Humans; Learning; Magnetic Resonance Imaging; Male; Motion Perception; Neuropsychological Tests; Nucleus Accumbens; Paroxetine; Reward; Selective Serotonin Reuptake Inhibitors; Sexual Behavior | 2016 |
Suicidal ideation declines with improvement in the subjective symptoms of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Treatment Outcome | 2018 |
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Suicide, Attempted; Treatment Outcome | 2018 |
46 other study(ies) available for bupropion and paroxetine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Paroxetine/bupropion combination treatment for refractory depression.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Middle Aged; Paroxetine | 1996 |
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
Topics: 1-Naphthylamine; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Bupropion; Dopamine Uptake Inhibitors; Female; Fluoxetine; Humans; Male; Middle Aged; Orgasm; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Drug Therapy, Combination; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Mood Disorders; Pain Measurement; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 1997 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Re: Managing depression refractory to SSRIs.
Topics: Adult; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Paroxetine; Treatment Outcome | 2000 |
Type II error and antidepressants.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Therapy, Combination; False Negative Reactions; Humans; Paroxetine; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 2001 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Combined antidepressant treatment: a risk factor for switching in bipolar patients.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Bupropion; Carbamazepine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Paroxetine; Risk Factors; Treatment Outcome | 2002 |
Risk factors for falls during treatment of late-life depression.
Topics: Accidental Falls; Age Factors; Aged; Antidepressive Agents; Blood Pressure; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Hypotension, Orthostatic; Male; Multivariate Analysis; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Psychotherapy; Risk Factors; Selective Serotonin Reuptake Inhibitors; Survival Analysis | 2002 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Bupropion; Citalopram; Depression; Desipramine; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Hindlimb Suspension; Imipramine; Male; Mice; Mice, Inbred Strains; Paroxetine; Selective Serotonin Reuptake Inhibitors; Species Specificity | 2003 |
Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bupropion; Chemotherapy, Adjuvant; Dibenzothiazepines; Evidence-Based Medicine; Humans; Multiple Myeloma; Paroxetine; Quetiapine Fumarate; Treatment Outcome | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Recurrent paroxetine-induced hyponatremia.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Recurrence; Sodium Chloride | 2004 |
Maintenance treatment of depression in old age.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Paroxetine; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2006 |
Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Fatigue Syndrome, Chronic; Female; Humans; Paroxetine; Psychiatric Status Rating Scales | 2006 |
Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium Compounds; Male; Nortriptyline; Paroxetine; Psychotherapy; Secondary Prevention; Time Factors; Treatment Outcome | 2007 |
Psychopharmacology news.
Topics: Antidepressive Agents; Bupropion; Congresses as Topic; Dopamine Uptake Inhibitors; Drug Industry; Humans; Paroxetine; Randomized Controlled Trials as Topic; Smoking Prevention | 2007 |
Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Humans; Logistic Models; Multicenter Studies as Topic; Paroxetine; Patient Selection; Signal Detection, Psychological; Treatment Outcome | 2008 |
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Bupropion; Cognition Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2008 |
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sex Factors | 2009 |
When is a "generic" medication not really a generic?
Topics: Bupropion; Cyclohexanols; Drug Costs; Drug Labeling; Drug Prescriptions; Drugs, Generic; Humans; Marketing of Health Services; Paroxetine; Patient Selection; Psychiatric Nursing; Psychotropic Drugs; Therapeutic Equivalency; United States; United States Food and Drug Administration; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion.
Topics: Aged; Analgesics, Opioid; Anesthesia, General; Bupropion; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Fentanyl; Humans; Mastectomy; Ondansetron; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiophenes | 2012 |
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Bupropion; CA3 Region, Hippocampal; Depressive Disorder, Major; Disease Models, Animal; Dorsal Raphe Nucleus; Locus Coeruleus; Male; Olfactory Bulb; Paroxetine; Piperazines; Pyramidal Cells; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonergic Neurons; Serotonin Antagonists; Ventral Tegmental Area | 2014 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressure Liquid; Cyclopropanes; Depressive Disorder; Desipramine; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Piperidines; Receptors, N-Methyl-D-Aspartate | 2017 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Bupropion; Drug Therapy, Combination; Male; Maze Learning; Memory Disorders; Paroxetine; Rats; Rats, Wistar; Spatial Memory; Venlafaxine Hydrochloride | 2018 |
Effects of long-term paroxetine or bupropion treatment on puberty onset, reproductive and feeding parameters in adolescent male rats.
Topics: Adolescent; Animals; Antidepressive Agents; Bupropion; Fertility; Humans; Male; Models, Animal; Paroxetine; Rats; Rats, Sprague-Dawley; Sexual Maturation; Sperm Motility; Spermatozoa; Testis; Time Factors | 2019 |
Chronic exposure to paroxetine or bupropion modulates the pubertal maturation and the reproductive system in female rats.
Topics: Animals; Anti-Mullerian Hormone; Antidepressive Agents, Second-Generation; Bupropion; Eating; Estradiol; Female; Genitalia; Luteinizing Hormone; Organ Size; Ovary; Paroxetine; Rats; Rats, Sprague-Dawley; Sexual Maturation; Uterus | 2020 |
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Topics: Antidepressive Agents; Atenolol; Bisoprolol; Bupropion; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Fluoxetine; Humans; Metoprolol; Paroxetine; Retrospective Studies | 2022 |